Warren Buffett approves investing in NOVO NORDISK A/S

From Nasdaq: 2025-01-20 09:00:00

Validea’s guru fundamental report for NOVO NORDISK A/S (ADR) (NVO) shows the stock rates highest using Warren Buffett’s Patient Investor model, indicating strong interest. NVO is a large-cap growth stock in the Biotechnology & Drugs industry, scoring 100% based on fundamentals and valuation. The stock passes all of Buffett’s strategy tests, including earnings predictability, debt service, and return on equity. Warren Buffett, known for his successful investing track record, has consistently outperformed the market for decades and is considered one of the greatest investors of all time. Validea is an investment research service that follows the strategies of investment legends like Buffett.



Read more at Nasdaq: Warren Buffett Detailed Fundamental Analysis – NVO